Allogeneic Hematopoietic Cell Transplantation for Chronic Myelofibrosis in Australia and New Zealand: Older Recipients Receiving Myeloablative Conditioning at Increased Mortality Risk

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 2, 2012, Pages 302-308

  Nivison Smith, Ian ^a   Dodds, Anthony J ^b   Butler, Jason ^c   Bradstock, Kenneth F ^d   Ma, David D F ^b   Simpson, Judy M ^e   Szer, Jeff ^f  

^a ABMTRR   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Allogeneic hematopoeitic cell transplantation; Chronic myelofibrosis

Indexed keywords

BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUSTRALIA; CAUSE OF DEATH; CHRONIC DISEASE; CHRONIC MYELOFIBROSIS; ENGRAFTMENT; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; INFECTIOUS COMPLICATION; INTERSTITIAL PNEUMONIA; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOFIBROSIS; NEW ZEALAND; OVERALL SURVIVAL; RELAPSE; RETROSPECTIVE STUDY; SPLENOMEGALY; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AUSTRALIA; CHRONIC DISEASE; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; PRIMARY MYELOFIBROSIS; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855588064     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.05.003     Document Type: Article

References (27)

1. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000, 342:1255-1265.
2. Guardiola P., Anderson J.E., Bandini G., et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center collaborative study. Blood 1999, 93:2831-2838.
3. Dupriez B., Morel P., Demory J.L., et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996, 88:1013-1018.
4. Tefferi A., Mesa R.A., Schroeder G., Hanson C.A., Li C.Y., Dewald G.W. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol 2001, 113:763-771.
5. Larsen T.S., Christensen J.H., Hasselbalch H.C., Pallisgaard N. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol 2007, 136:745-751.
6. Kroger N., Badbaran A., Holler E., et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007, 109:1316-1321.
7. Guglielmelli P., Barosi G., Specchia G., et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009, 114:1477-1483.
8. Demory J.L., Dupriez B., Fenaux P., et al. Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases. Blood 1988, 72:855-859.
9. Rupoli S., Da Lio L., Sisti S., et al. Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival. Ann Hematol 1994, 68:205-212.
10. Cervantes F., Pereira A., Esteve J., et al. Identification of " short-lived" and " long-lived" patients at presentation of idiopathic myelofibrosis. Br J Haematol 1997, 97:635-640.
11. Papageorgiou S.G., Castleton A., Bloor A., Kottaridis P.D. Allogeneic stem cell transplantation as treatment for myelofibrosis. Bone Marrow Transplant 2006, 38:721-727.
12. Kerbauy D.M., Gooley T.A., Sale G.E., et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant 2007, 13:355-365.
13. Daly A., Song K., Nevill T., et al. Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplant 2003, 32:35-40.
14. Ditschkowski M., Beelen D.W., Trenschel R., Koldehoff M., Elmaagacli A.H. Outcome of allogeneic stem cell transplantation in patients with myelofibrosis. Bone Marrow Transplant 2004, 34:807-813.
15. Patriarca F., Bacigalupo A., Sperotto A., et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica 2008, 93:1514-1522.
16. Kroger N., Zabelina T., Schieder H., et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 2005, 128:690-697.
17. Merup M., Lazarevic V., Nahi H., et al. Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br J Haematol 2006, 135:367-373.
18. Rondelli D., Barosi G., Bacigalupo A., et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005, 105:4115-4119.
19. Snyder D.S., Palmer J., Stein A.S., et al. Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. Biol Blood Marrow Transplant 2006, 12:1161-1168.
20. Kröger N., Holler E., Kobbe G., et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group forBlood and Marrow Transplantation. Blood 2009, 114:5264-5270.
21. Ballen K.K., Shrestha S., Sobocinski K.A., et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010, 16:358-367.
22. Stewart W.A., Pearce R., Kirkland K.E., et al. The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. Bone Marrow Transplant 2010, 45:1587-1593.
23. Nivison-Smith I., Bradstock K.F., Dodds A.J., et al. Hematopoietic stem cell transplantation in Australia and New Zealand, 1992-2004. Biol Blood Marrow Transplant 2007, 13:905-912.
24. Thomas E., Storb R., Clift R.A., et al. Bone-marrow transplantation. N Engl J Med 1975, 292:832-843.
25. Barosi G., Bordessoule D., Briere J., et al. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood 2005, 106:2849-2853.
26. George B., Kerridge I., Gottlieb D., et al. A reduced intensity conditioning protocol associated with excellent survival in patients with myelofibrosis. Bone Marrow Transplant 2008, 42:567-568.
27. Robin M., Tabrizi R., Mohty M., et al. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Br J Haematol 2010, 152:331-339.